We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

23 hedge funds and large institutions have $48.9M invested in ProQR Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

28% more funds holding

Funds holding: 18 → 23 (+5)

1.64% more ownership

Funds ownership: 38.56% → 40.2% (+1.6%)

4% more capital invested

Capital invested by funds: $46.8M → $48.9M (+$2.06M)

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$5.19M
2
SFM
Sphera Funds Management
Israel
+$1.04M
3
Morgan Stanley
Morgan Stanley
New York
+$205K
4
Wells Fargo
Wells Fargo
California
+$153K
5
NCCM
Nine Chapters Capital Management
New Jersey
+$142K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
-$1.29M
2
Jennison Associates
Jennison Associates
New York
-$79.2K
3
O
OrbiMed
New York
-$52.4K
4
Creative Planning
Creative Planning
Kansas
-$10K
5
ClearBridge Investments
ClearBridge Investments
New York
-$6.34K

PRQR Hedge Fund Activity: Q3 2017 in Review

23 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2017, worth a combined $48.9M — up 4.4% from $46.8M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PRQR positions and 1 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Artal Group, adding an estimated $5.19M. The largest seller was Janus Henderson Group, cutting an estimated $1.29M.

  • 23 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2017, up from 18 in Q2 2017.
  • Funds reported $48.9M of ProQR Therapeutics stock for Q3 2017, up 4.4% quarter-over-quarter.
  • 6 funds opened new ProQR Therapeutics positions in Q3 2017 and 1 closed out, a net change of +5 holders.
  • The largest ProQR Therapeutics buyer in Q3 2017 was Artal Group, an estimated $5.19M added.
  • The largest ProQR Therapeutics seller in Q3 2017 was Janus Henderson Group, an estimated $1.29M sold.

Based on aggregated 13F filings for Q3 2017.